'I Get to Help Others': Meet The First Patient in City of Hope's COVID Vaccine Trial

Francesca Billington

Francesca Billington is a freelance reporter. Prior to that, she was a general assignment reporter for dot.LA and has also reported for KCRW, the Santa Monica Daily Press and local publications in New Jersey. She graduated from Princeton in 2019 with a degree in anthropology.

'I Get to Help Others': Meet The First Patient in City of Hope's COVID Vaccine Trial

Last month, Lupe Duarte read an announcement from her colleagues that City of Hope was recruiting for a COVID-19 vaccine trial. The mother of three, who also cares for her infirm parents, volunteered immediately.

This afternoon the 48-year old project manager became the first patient to get a dose of the vaccine developed by a team of researchers at City of Hope.

She's part of the biotech institution's phase 1 trial, which tests a drug's safety typically over one to two years. The process is likely to last just three months as regulators speed up approval to deal with the pandemic. The next stage, expected to span about eight months, would test on more volunteers and further assess safety and efficacy.


City of Hope is one of only a handful of Southern California organizations that are working on a vaccine. Their shot will require two doses and must be stored about 60 degrees below celsius, but the team is looking into whether it can be freeze dried and stored at room temperature.

"I think a lot of people still fear the clinical trial aspect," said Duarte, who is expecting a few check-in calls this weekend and plans to visit the clinic for regular blood samples. "There is no doubt in my mind that this is safe for me."

Duarte is no stranger to the trial process. She's worked in clinical research since 1996, beginning with prostate and lung cancer studies. Over this next year, as Duarte is monitored and observed for side effects to the vaccine, she'll experience clinical trials as a patient instead.

"If I'm healthy and I'm eligible and I get to participate, why shouldn't I?" she said. "I get to help others, like our cancer patients have done over the years."

She wants more people of color and Latinos, who have been especially hard hit in the pandemic, to participate in clinical trials.

Across the country, an estimated 237 biotech companies and research labs have joined the race to develop their own vaccinations as pharmaceutical giants prepare for the first wave of mass distributions. Just 38 of those, including the vaccine from City of Hope, have started clinical testing.

Very few companies will pull it off. Over 90% of clinical trials fail, said Esther Krofah, executive director of the Milken Institute's FasterCures. Her team has tracked vaccine makers since March, when just a couple dozen companies had entered phase 1 trials.

"We need to make sure we have incentives for second and third generation vaccines, to get as many of them over the finish line," she said. "The goal would be to have a handful or more that can meet the global demand."

Krofah said factors like temperature storage matter most when it comes time to distribute. But some vaccines in development do have a leg up, she said, including those requiring just a single dose.

"Those are very hopeful in that you might be able to scale without the burden of somebody coming back twice," she said.

Don J. Diamond, a City of Hope professor and vaccine researcher, said his team received the Federal Drug Association's go-ahead to start human trials for the vaccine a few weeks ago. Their vaccine utilizes a synthetic platform technology called an MVA to trigger the immune system by stimulating antibodies and T cells.

Duarte and her five siblings rotate as caretakers for their mother, who is bed-bound and immunocompromised. Her father was recently diagnosed with prostate cancer. The vaccination gives her some sense of relief that she won't put her parents at risk.

"Cancer doesn't stop," she said by Zoom, hours before she would drive from her home in Glendora to the clinic in Duarte. "We still have to continue taking care of our parents."

In 28 days, Duarte will be back for her second dose.

https://twitter.com/frosebillington
francesca@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

Diankha Linear on How Community Is Revolutionizing Text Marketing

Spencer Rascoff

Spencer Rascoff serves as executive chairman of dot.LA. He is an entrepreneur and company leader who co-founded Zillow, Hotwire, dot.LA, Pacaso and Supernova, and who served as Zillow's CEO for a decade. During Spencer's time as CEO, Zillow won dozens of "best places to work" awards as it grew to over 4,500 employees, $3 billion in revenue, and $10 billion in market capitalization. Prior to Zillow, Spencer co-founded and was VP Corporate Development of Hotwire, which was sold to Expedia for $685 million in 2003. Through his startup studio and venture capital firm, 75 & Sunny, Spencer is an active angel investor in over 100 companies and is incubating several more.

​Diankha Linear
Diankha Linear

On this episode of Office Hours, Community CEO Diankha Linear joins host Spencer Rascoff to discuss her foray into the startup world and the strategic approaching to scaling up.

Read moreShow less
https://twitter.com/spencerrascoff
https://www.linkedin.com/in/spencerrascoff/
admin@dot.la

LA Tech ‘Moves’: Dreamscape, LinQuest and PetDX Gain New CEOs

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

LA Tech ‘Moves’: Dreamscape, LinQuest and PetDX Gain New CEOs

“Moves,” our roundup of job changes in L.A. tech, is presented by Interchange.LA, dot.LA's recruiting and career platform connecting Southern California's most exciting companies with top tech talent. Create a free Interchange.LA profile here—and if you're looking for ways to supercharge your recruiting efforts, find out more about Interchange.LA's white-glove recruiting service by emailing Sharmineh O’Farrill Lewis (sharmineh@dot.la). Please send job changes and personnel moves to moves@dot.la.

***

Read moreShow less

This Week in ‘Raises’: ADARx Pharmaceuticals Lands $46M, PLAI Labs Scores $32M

Decerry Donato

Decerry Donato is a reporter at dot.LA. Prior to that, she was an editorial fellow at the company. Decerry received her bachelor's degree in literary journalism from the University of California, Irvine. She continues to write stories to inform the community about issues or events that take place in the L.A. area. On the weekends, she can be found hiking in the Angeles National forest or sifting through racks at your local thrift store.

This Week in ‘Raises’: ADARx Pharmaceuticals Lands $46M, PLAI Labs Scores $32M
This Week in ‘Raises’: ContractSafe Inks $27.5M, Deal Box Collects $125M

A local RNA base-editing platform raised fresh funding to advance its drug development pipeline, while a local Web3 company founded by former MySpace and Jam City founders Chris DeWolfe and Aber Whitcomb scored funding to build out an artificial intelligence backed by generative AI that allows users to create and upload their own digital assets to the game.

***

Read moreShow less
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending